329 related articles for article (PubMed ID: 29989342)
21. Post-progression survival is highly linked to overall survival in patients with non-small-cell lung cancer harboring sensitive EGFR mutations treated with first-line epidermal growth factor receptor-tyrosine kinase inhibitors.
Imai H; Kaira K; Mori K; Kotake M; Mitani M; Kawashima N; Hisada T; Minato K
Thorac Cancer; 2019 Dec; 10(12):2200-2208. PubMed ID: 31595714
[TBL] [Abstract][Full Text] [Related]
22. Incorporating circulating tumor DNA detection to radiographic assessment for treatment response in advanced EGFR-mutant lung cancer.
Kok PS; Lee K; Lord S; John T; Marschner I; Wu YL; Mok TSK; Lee CK
Lung Cancer; 2022 Jan; 163():14-18. PubMed ID: 34894454
[TBL] [Abstract][Full Text] [Related]
23. Impact of detecting plasma EGFR mutations with ultrasensitive liquid biopsy in outcomes of NSCLC patients treated with first- or second-generation EGFR-TKIs.
Arrieta O; Hernandez-Martinez JM; Montes-Servín E; Heredia D; Cardona AF; Molina-Romero C; Lara-Mejía L; Diaz-Garcia D; Bahena-Gonzalez A; Mendoza-Oliva DL
Cancer Biomark; 2021; 32(2):123-135. PubMed ID: 34057135
[TBL] [Abstract][Full Text] [Related]
24. EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291.
Thress KS; Brant R; Carr TH; Dearden S; Jenkins S; Brown H; Hammett T; Cantarini M; Barrett JC
Lung Cancer; 2015 Dec; 90(3):509-15. PubMed ID: 26494259
[TBL] [Abstract][Full Text] [Related]
25. Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patients.
Boysen Fynboe Ebert E; McCulloch T; Holmskov Hansen K; Linnet H; Sorensen B; Meldgaard P
Lung Cancer; 2020 May; 143():67-72. PubMed ID: 32213382
[TBL] [Abstract][Full Text] [Related]
26. Clinical Outcomes in Non-Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling.
Tran HT; Lam VK; Elamin YY; Hong L; Colen R; Elshafeey NA; Hassan ISA; Altan M; Blumenschein GR; Rinsurongkawong W; Rivera MJ; Vasquez ME; Carter BW; Byers LE; Tsao AS; Gibbons DL; Fossella F; Glisson BS; Zhang J; Heymach JV
JCO Precis Oncol; 2021 Aug; 5():. PubMed ID: 34377884
[TBL] [Abstract][Full Text] [Related]
27. Circulating tumor DNA analysis of EGFR-mutant non-small cell lung cancer patients receiving osimertinib following previous tyrosine kinase inhibitor treatment.
Beagan JJ; Bach S; van Boerdonk RA; van Dijk E; Thunnissen E; van den Broek D; Weiss J; Kazemier G; Pegtel DM; Bahce I; Ylstra B; Heideman DAM
Lung Cancer; 2020 Jul; 145():173-180. PubMed ID: 32460198
[TBL] [Abstract][Full Text] [Related]
28. Predictive value of early kinetics of ctDNA combined with cfDNA and serum CEA for EGFR-TKI treatment in advanced non-small cell lung cancer.
Zheng J; Wang Y; Hu C; Zhu M; Ii J; Lin C; Lu C; Dou Y; Zhao C; Zhang Y; Wu D; Li L; Tang H; He T; Pan C; Han R; He Y
Thorac Cancer; 2022 Nov; 13(22):3162-3173. PubMed ID: 36193794
[TBL] [Abstract][Full Text] [Related]
29. Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI-Treated Patients with EGFR-Mutant NSCLC (SWOG S1403).
Mack PC; Miao J; Redman MW; Moon J; Goldberg SB; Herbst RS; Melnick MA; Walther Z; Hirsch FR; Politi K; Kelly K; Gandara DR
Clin Cancer Res; 2022 Sep; 28(17):3752-3760. PubMed ID: 35713632
[TBL] [Abstract][Full Text] [Related]
30. Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer.
Roosan MR; Mambetsariev I; Pharaon R; Fricke J; Husain H; Reckamp KL; Koczywas M; Massarelli E; Bild AH; Salgia R
Chest; 2021 Sep; 160(3):1095-1107. PubMed ID: 33878340
[TBL] [Abstract][Full Text] [Related]
31. The Allele Frequency of EGFR Mutations Predicts Survival in Advanced EGFR T790M-Positive Non-small Cell Lung Cancer Patients Treated with Osimertinib.
Buder A; Hochmair MJ; Filipits M
Target Oncol; 2021 Jan; 16(1):77-84. PubMed ID: 33270169
[TBL] [Abstract][Full Text] [Related]
32. Epidermal growth factor receptor (EGFR) T790M mutation identified in plasma indicates failure sites and predicts clinical prognosis in non-small cell lung cancer progression during first-generation tyrosine kinase inhibitor therapy: a prospective observational study.
Zhang S; Zhu L; Xia B; Chen E; Zhao Q; Zhang X; Chen X; Chen X; Ma S
Cancer Commun (Lond); 2018 May; 38(1):28. PubMed ID: 29789021
[TBL] [Abstract][Full Text] [Related]
33. Role of Circulating Tumor DNA Profiling in Patients with Non-Small Cell Lung Cancer Treated with EGFR Inhibitor.
Ku BM; Kim YJ; Park D; Lee SH; Ahn JS; Park K; Ahn MJ; Sun JM
Oncology; 2022; 100(4):228-237. PubMed ID: 35196661
[TBL] [Abstract][Full Text] [Related]
34. Longitudinal monitoring of ctDNA EGFR mutation burden from urine correlates with patient response to EGFR TKIs: A case series.
Tchekmedyian N; Mudad R; Blanco FF; Raymond VM; Garst J; Erlander MG; Haura E; Berz D
Lung Cancer; 2017 Jun; 108():22-28. PubMed ID: 28625639
[TBL] [Abstract][Full Text] [Related]
35. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
[TBL] [Abstract][Full Text] [Related]
36. Predicting osimertinib-treatment outcomes through EGFR mutant-fraction monitoring in the circulating tumor DNA of EGFR T790M-positive patients with non-small cell lung cancer (WJOG8815L).
Sakai K; Takahama T; Shimokawa M; Azuma K; Takeda M; Kato T; Daga H; Okamoto I; Akamatsu H; Teraoka S; Ono A; Ohira T; Yokoyama T; Yamamoto N; Nakagawa K; Nishio K
Mol Oncol; 2021 Jan; 15(1):126-137. PubMed ID: 33131198
[TBL] [Abstract][Full Text] [Related]
37. Clinical utility of plasma EGFR mutation detection with quantitative PCR in advanced lung cancer: A meta-analysis.
Kok PS; Lee K; Lord S; Yang JC; Rosell R; Goto K; John T; Wu YL; Mok TSK; Lee CK
Lung Cancer; 2021 Apr; 154():113-117. PubMed ID: 33647577
[TBL] [Abstract][Full Text] [Related]
38. Comparison of the efficacies of first-generation epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
Aiko N; Shimokawa T; Miyazaki K; Misumi Y; Agemi Y; Ishii M; Nakamura Y; Yamanaka T; Okamoto H
BMC Cancer; 2018 Oct; 18(1):1012. PubMed ID: 30348116
[TBL] [Abstract][Full Text] [Related]
39. Distinct clinical outcomes of non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors: non-responders versus responders.
Hsiao SH; Liu HE; Lee HL; Lin CL; Chen WY; Wu ZH; Lin SE; Chiang LL; Chung CL
PLoS One; 2013; 8(12):e83266. PubMed ID: 24376677
[TBL] [Abstract][Full Text] [Related]
40. Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.
Tanaka K; Hata A; Kaji R; Fujita S; Otoshi T; Fujimoto D; Kawamura T; Tamai K; Takeshita J; Matsumoto T; Monden K; Nagata K; Otsuka K; Nakagawa A; Tachikawa R; Otsuka K; Tomii K; Katakami N
J Thorac Oncol; 2013 Jul; 8(7):892-8. PubMed ID: 23591159
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
